Supplier
Pantherx Specialty LLC
Pantherx Specialty LLC was paid $64.93M by Medicaid between Jan 2018 and Jun 2024, across 12 billing codes. Its largest line is J0584, Injection, burosumab-twza 1 mg — 88% of everything it billed.
33Billing provider infoPANTHERX SPECIALTY LLC
PITTSBURGH, PA 15275
PITTSBURGH, PA 15275
33aNPI1316213531assigned 04/02/2012
33bProvider typePharmacy
28Total paid$64.93M
24GClaims19,626
24DCodes billed12
24AFirst – last monthJan 2018 – Jun 2024
Compared with peers
Next to other Pharmacy providers in Pennsylvania
Rank by total paid#1 of 51
Median peer was paid$4K
This provider vs. median15,504×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,203 | $700K | |
| 2019 | 3,684 | $6.30M | |
| 2020 | 4,315 | $8.25M | |
| 2021 | 3,651 | $13.37M | |
| 2022 | 3,019 | $14.31M | |
| 2023 | 2,182 | $13.41M | |
| 2024incomplete | 572 | $8.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0584 | Injection, burosumab-twza 1 mg | 88% | 4,457 | 1,983 | $57.37M |
| J3316 | Injection, triptorelin, extended-release, 3.75 mg | 10.0% | 437 | 378 | $6.47M |
| J3590 | Unclassified biologics | <1% | 44 | 25 | $511K |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | <1% | 4,767 | 2,545 | $177K |
| J7503 | Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg | <1% | 846 | 770 | $127K |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | <1% | 2,847 | 2,646 | $110K |
| J7518 | Mycophenolic acid, oral, 180 mg | <1% | 1,284 | 1,128 | $86K |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | <1% | 1,779 | 1,335 | $59K |
| J7517 | Mycophenolate mofetil, oral, 250 mg | <1% | 1,500 | 1,236 | $9K |
| J7508 | Tacrolimus, extended release, (astagraf xl), oral, 0.1 mg | <1% | 115 | 69 | $9K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,520 | 1,381 | $4K |
| Q0510 | Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant | <1% | 30 | 22 | $880.77 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSNYDER, ROBERT (CEO)
| Provider | Location | Paid |
|---|---|---|
| Pantherx Specialty LLC | Pittsburgh, PA | $22.55M |
| Pantherx Specialty LLC | Coraopolis, PA | $7.74M |
| Arista Home Care LLC | Brooklyn, NY | $6.88M |
| Mid Michigan Anesthesiology Group, PC | Midland, MI | $472K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.